TheraVac Biotech

🚀 Announcing NeoVax®: Pioneering Personalized Cancer Vaccines for the Future of Precision Medicine! 🚀 At #Genovate® Platform, we're thrilled to unveil #NeoVax®, a revolutionary module within TheraVac Biotech, focused on transforming cancer treatment through personalized neoantigen vaccines✨🌐 Why NeoVax®? NeoVax taps into the cutting-edge of immunotherapy by targeting unique mutations (neoantigens) in cancer cells, creating tailor-made vaccines designed to trigger a powerful immune response. Our precision-driven approach identifies, optimizes, and validates the most immunogenic fragments, offering new hope in the fight against aggressive cancers. How It Works NeoVax leverages AI-powered platforms for: 1- Neoantigen Identification & Selection - Harnessing Genovate’s data resources to pinpoint high-potential neoantigen targets. 2- Peptide Synthesis & Optimization - Utilizing molecular docking, MD simulations, and ADMET profiling to refine peptide designs. 3- Vaccine Formulation & Validation - Formulating vaccines through in silico and preclinical trials, moving towards clinical and regulatory milestones with high success projections. Seamless Collaboration & Compliance Integrated with the Genovate ecosystem, NeoVax bridges R&D with regulatory workflows through decentralized, transparent digital twins, ensuring compliance, data integrity, and accelerated approval processes. The Future of Cancer Treatment is Here NeoVax embodies a vision where precision medicine is accessible, tailored, and impactful for every patient. Together with our partners and the wider community, we’re bringing personalized cancer vaccines from concept to clinic. Stay tuned as we move forward with clinical trials, innovative partnerships, and groundbreaking results! Learn more and join us in shaping the future of precision oncology!🧬💡 Dr. Isaad Sainkoudje Marie N. Mendez-Sainkoudje Sirrena Caelis Caroline Rodriguez Samuel Craft Raphael Wenninger TradePharma Network TradePharmaDAO Omniversalis Impact Fund BayesLearn Systems SirrenaAI OmniversalisDAO #Innovation #RnD #Biotech #TheraVacBiotech #InSilico #AIinHealthcare #RegulatoryCompliance #Biologics #NeoAntigens #PreclinicalTrials #ClinicalTrials #PrecisionMedicine #OmniComm #OmniTwin

[Retour sur] La mission d’étude à Bruxelles sur réglementation des dispositifs médicaux, intelligence artificielle et cyber-résilience 🩺 ⚖️ La réglementation européenne impacte fortement le secteur des dispositifs médicaux et de la santé. Fort de ce constat, des laboratoires de recherche et des entreprises ont pris part à la mission d'étude coorganisée avec Biotech Santé Bretagne auprès de représentants des instances européennes autour de la réglementation et du règlement européen sur les dispositifs médicaux MDR2017/745.   2 jours riches en échanges pour les participants et une occasion unique de pouvoir défendre leurs intérêts en faisant remonter les difficultés rencontrées dans la mise en œuvre des réglementations européennes. 💡 Les temps forts : ➡️ Point d’actualité sur les règlements relatifs aux dispositifs médicaux (DM et DM DIV) ➡️ Impact du Digital Market Act et du Digital Services Act sur le secteur de la santé ➡️ Présentation du futur règlement européen sur l’intelligence artificielle (AI Act) ➡️ Cyberrésilience et produits de santé : défis et opportunités   Ce qu'il faut retenir : 1️⃣ Une volonté forte des entreprises de respecter les règles européennes pour garantir des produits de santé sécurisés et de qualité. 2️⃣ Des défis à relever pour favoriser la mise en œuvre de la réglementation DM : un faible nombre d’organismes notifiés, une lente montée en compétence sur l’application des normes harmonisées, et l'absence d'une structure officielle européenne (comme la FDA aux USA) pour guider et accompagner les acteurs du secteur. 3️⃣Ces difficultés freinent la compétitivité de l’UE et contribuent à la fuite des innovations vers des pays non membres de l’UE, tels que les USA. 🤝 Ensemble, 𝐜𝐨𝐧𝐭𝐢𝐧𝐮𝐨𝐧𝐬 𝐚̀ œ𝐮𝐯𝐫𝐞𝐫 𝐩𝐨𝐮𝐫 𝐮𝐧 𝐜𝐚𝐝𝐫𝐞 𝐫𝐞́𝐠𝐥𝐞𝐦𝐞𝐧𝐭𝐚𝐢𝐫𝐞 𝐞𝐮𝐫𝐨𝐩𝐞́𝐞𝐧 𝐞𝐟𝐟𝐢𝐜𝐚𝐜𝐞 𝐞𝐭 𝐚𝐝𝐚𝐩𝐭𝐞́ 𝐚𝐮𝐱 𝐞𝐧𝐣𝐞𝐮𝐱 𝐝𝐞𝐬 𝐞𝐧𝐭𝐫𝐞𝐩𝐫𝐢𝐬𝐞𝐬 𝐝𝐞 𝐬𝐚𝐧𝐭𝐞́ ! 📩 Si vous souhaitez en savoir + sur cette action, contactez Sophie PAILLARD - Conseillère Affaires Réglementaires #EENOuest à Bretagne Compétitivité. 📢 Votre avis compte ! 2 consultations sont en cours : 𝗨𝗻𝗲 𝗰𝗼𝗻𝘀𝘂𝗹𝘁𝗮𝘁𝗶𝗼𝗻 𝗳𝗿𝗮𝗻𝗰̧𝗮𝗶𝘀𝗲 𝗾𝘂𝗶 𝗮 𝘃𝗼𝗰𝗮𝘁𝗶𝗼𝗻 𝗱𝗲 𝗽𝗲𝗿𝗺𝗲𝘁𝘁𝗿𝗲 𝗹’𝗮𝗱𝗮𝗽𝘁𝗮𝘁𝗶𝗼𝗻 𝗱𝗲 𝗽𝗼𝗹𝗶𝘁𝗶𝗾𝘂𝗲𝘀 𝗽𝘂𝗯𝗹𝗶𝗾𝘂𝗲𝘀 𝗱𝗲 𝘀𝗼𝘂𝘁𝗶𝗲𝗻 𝗮̀ 𝗹𝗮 𝗳𝗶𝗹𝗶𝗲̀𝗿𝗲 𝗽𝗼𝘂𝗿 𝗹𝗲 𝗿𝗲𝗻𝗳𝗼𝗿𝗰𝗲𝗺𝗲𝗻𝘁 𝗱𝗲 𝗹𝗮 𝗰𝗵𝗮𝗶̂𝗻𝗲 𝗱’𝗮𝗽𝗽𝗿𝗼𝘃𝗶𝘀𝗶𝗼𝗻𝗻𝗲𝗺𝗲𝗻𝘁 𝗱𝗲𝘀 𝗱𝗶𝘀𝗽𝗼𝘀𝗶𝘁𝗶𝗳𝘀 𝗺𝗲́𝗱𝗶𝗰𝗮𝘂𝘅 𝗲𝗻 𝗙𝗿𝗮𝗻𝗰𝗲 (ouverte jusqu’au 21.02.25) : https://lnkd.in/ebgmHtRF 𝗨𝗻𝗲 𝗰𝗼𝗻𝘀𝘂𝗹𝘁𝗮𝘁𝗶𝗼𝗻 𝗲𝘂𝗿𝗼𝗽𝗲́𝗲𝗻𝗻𝗲 𝗾𝘂𝗶 𝗮 𝗽𝗼𝘂𝗿 𝗼𝗯𝗷𝗲𝗰𝘁𝗶𝗳 𝗱’𝗲́𝘃𝗮𝗹𝘂𝗲𝗿 𝗹𝗲𝘀 𝗽𝗲𝗿𝗳𝗼𝗿𝗺𝗮𝗻𝗰𝗲𝘀 𝗱𝗲 𝗹𝗮 𝗹𝗲́𝗴𝗶𝘀𝗹𝗮𝘁𝗶𝗼𝗻 (𝗥𝗲̀𝗴𝗹𝗲𝗺𝗲𝗻𝘁 (𝗨𝗘) 𝗻°𝟮𝟬𝟭𝟳/𝟳𝟰𝟱 𝗲𝘁 𝟳𝟰𝟲) (ouverte jusqu’au 21.03.25 : https://lnkd.in/emHwpyxU Bretagne Compétitivité I Solutions&co #EENCanHelp #RéglementationEuropéenne #MedicalDevices #Regulatory

💡 Au cœur des institutions européennes pour anticiper et ouvrir des discussions sur les futures réglementations du secteur des technologies médicales.   Biotech Santé Bretagne a organisé et accompagné une mission à Bruxelles la semaine dernière. L’objectif était de mieux anticiper et comprendre les futures réglementations, mais aussi de défendre les intérêts des acteurs de la santé en faisant remonter les difficultés rencontrées dans la mise en œuvre des réglementations européennes : règlements relatifs aux 𝗗𝗠 et 𝗗𝗠 𝗗𝗜𝗩, 𝗜𝗔 𝗔𝗰𝘁 et 𝗖𝘆𝗯𝗲𝗿 𝗥𝗲𝘀𝗶𝗹𝗶𝗲𝗻𝗰𝗲 𝗔𝗰𝘁. 🙏 Nous tenions à remercier toutes les personnes qui nous ont reçues : Mario Gabrielli Cossellu pour la commission sur la réglementation DM et DM DIV, Benjamin Meany MedTech Europe, Mme la députée Isabelle Le Callennec et Lucas Grandjean assistant parlementaire de Mr Laurent Castillo, Irène Georgiopoulos conseillère Santé pour la RF France. Merci également à la délégation de la Région Bretagne pour son accueil. Cette mission a été organisée en partenariat avec Bretagne Compétitivité, EEN Ouest (Bretagne - Pays de la Loire) et Solutions&co. 📩 Vous avez une question sur cette mission ? Contactez notre chargée de projets européens Adeline Jacob ou notre responsable du développement de la filière santé Guirec Hillion. 📢 Votre avis compte ! Deux consultations sont actuellement en cours : 𝗨𝗻𝗲 𝗰𝗼𝗻𝘀𝘂𝗹𝘁𝗮𝘁𝗶𝗼𝗻 𝗳𝗿𝗮𝗻𝗰̧𝗮𝗶𝘀𝗲 𝗾𝘂𝗶 𝗮 𝘃𝗼𝗰𝗮𝘁𝗶𝗼𝗻 𝗱𝗲 𝗽𝗲𝗿𝗺𝗲𝘁𝘁𝗿𝗲 𝗹’𝗮𝗱𝗮𝗽𝘁𝗮𝘁𝗶𝗼𝗻 𝗱𝗲 𝗽𝗼𝗹𝗶𝘁𝗶𝗾𝘂𝗲𝘀 𝗽𝘂𝗯𝗹𝗶𝗾𝘂𝗲𝘀 𝗱𝗲 𝘀𝗼𝘂𝘁𝗶𝗲𝗻 𝗮̀ 𝗹𝗮 𝗳𝗶𝗹𝗶𝗲̀𝗿𝗲 𝗽𝗼𝘂𝗿 𝗹𝗲 𝗿𝗲𝗻𝗳𝗼𝗿𝗰𝗲𝗺𝗲𝗻𝘁 𝗱𝗲 𝗹𝗮 𝗰𝗵𝗮𝗶̂𝗻𝗲 𝗱’𝗮𝗽𝗽𝗿𝗼𝘃𝗶𝘀𝗶𝗼𝗻𝗻𝗲𝗺𝗲𝗻𝘁 𝗱𝗲𝘀 𝗱𝗶𝘀𝗽𝗼𝘀𝗶𝘁𝗶𝗳𝘀 𝗺𝗲́𝗱𝗶𝗰𝗮𝘂𝘅 𝗲𝗻 𝗙𝗿𝗮𝗻𝗰𝗲 (ouverte jusqu’au 21 mars 2025) : https://lnkd.in/ebgmHtRF 𝗨𝗻𝗲 𝗰𝗼𝗻𝘀𝘂𝗹𝘁𝗮𝘁𝗶𝗼𝗻 𝗲𝘂𝗿𝗼𝗽𝗲́𝗲𝗻𝗻𝗲 𝗾𝘂𝗶 𝗮 𝗽𝗼𝘂𝗿 𝗼𝗯𝗷𝗲𝗰𝘁𝗶𝗳 𝗱’𝗲́𝘃𝗮𝗹𝘂𝗲𝗿 𝗹𝗲𝘀 𝗽𝗲𝗿𝗳𝗼𝗿𝗺𝗮𝗻𝗰𝗲𝘀 𝗱𝗲 𝗹𝗮 𝗹𝗲́𝗴𝗶𝘀𝗹𝗮𝘁𝗶𝗼𝗻 (𝗥𝗲̀𝗴𝗹𝗲𝗺𝗲𝗻𝘁 (𝗨𝗘) 𝗻°𝟮𝟬𝟭𝟳/𝟳𝟰𝟱 𝗲𝘁 𝟳𝟰𝟲) est ouverte jusqu’au 21 février 2025 : https://lnkd.in/emHwpyxU

🚀 The Future of Movement is Here! We’re excited to unveil our latest video for OmniTwin, where innovation meets freedom. 🌟 Whether you’re an explorer, creator, or visionary, OmiTwin is designed to empower your journey, adapt to your world, and elevate how you move. 🌍✨ 🎥 Watch the video & experience the transformation. It’s time to redefine what’s possible and take control of every path ahead. Your potential. Your journey. Your OmiTwin. Dr. Isaad Sainkoudje Marie N. Mendez-Sainkoudje Sirrena Caelis Caroline Rodriguez Samuel Craft Raphael Wenninger SirrenaAI OmniversalisDAO Omniversalis Impact Fund #EmpoweredMotion #OmiTwinExperience #InnovationUnleashed #FutureOfMovement #ElevateYourJourney #SmartTech #Sustainability #FreedomToMove #TechForTomorrow #MVP #OmiTwin

The Future of Pharma: Balancing Innovation, Operational Excellence, and Digital Transformation: The pharma industry continues to evolve rapidly, and 2023-2024 offers fascinating insights into R&D spending and strategic shifts. Some companies have led the change, significantly outpacing the 10% industry average growth in R&D spending. At the same time, others have adopted more cautious approaches, recalibrating after their COVID-19 vaccine-driven peaks. But beyond spending, the real story lies in how these resources are being deployed and what strategies are shaping the future. Harnessing AI for Breakthroughs Generative AI (GenAI) is revolutionizing drug discovery and trial processes. Companies investing in AI-driven platforms are reducing clinical trial timelines and costs, opening up new opportunities. Decentralized Trials (DCTs) Companies embracing DCTs are democratizing research participation, making clinical trials more efficient and inclusive. This shift not only improves operational excellence but also aligns with sustainability goals by reducing logistical footprints. Strategic Ecosystem Building Partnerships are becoming the backbone of innovation. Collaborations with tech firms and biotechs are accelerating progress in data-driven drug development and creating new value chains across the industry. Operational Excellence through Digitalization Beyond R&D, companies must adopt digital tools to streamline supply chains, enhance decision-making, and optimize finance operations. Similarly, integrating advanced analytics in finance transformation is critical for long-term sustainability. Sustainability as Strategy With regulatory pressures mounting and pricing scrutiny intensifying, pharma companies must align growth with societal value. What’s Next?: As the industry advances, questions remain: 1)Should companies explore more automation in more support functions? 2)How can financial transformation and AI create synergies to future-proof operations? 3)What untapped therapeutic areas could become growth engines by 2026? The challenge isn’t just in choosing where to invest but in creating a cohesive strategy that balances innovation with operational excellence. What strategies do you think will dominate the next phase of pharma evolution? Let’s discuss. #PharmaInnovation, #GenerativeAI, #DecentralizedTrials #PrecisionMedicine, #OperationalExcellence, #DigitalTransformation #SustainabilityInPharma, #PharmaStrategy, #HealthcareFuture, #PharmaPartnerships, #FuturePharma Image Source: VisualCapitalist (WIPO Global Innovation Index 2024)

This development serves as a sobering reminder of the global threat posed by emerging infectious diseases like #MPOX. At TheraVac Biotech, we’re fully aware of the situation and working tirelessly to address it. 🚨 One #MPOX vaccine in our pipeline is TheraVac-MPOX-1: a novel biologic targeting two of the most promising genes/proteins among the six involved in MPOX pathogenesis, including #Clade1b. These proteins are critical to the virus's ability to infect host cells, expand its host range, and evade the immune system—making them prime candidates for therapeutic interventions. 🧬💉 As we advance this and other cutting-edge research projects, we remain committed to accelerating innovative solutions to combat global health threats. Together, we can build a more resilient future. 🌍🔬 Dr. Isaad Sainkoudje Marie N. Mendez-Sainkoudje Sirrena Caelis Caroline Rodriguez Samuel Craft Raphael Wenninger Omniversalis Impact Fund BayesLearn Systems SirrenaAI OmniversalisDAO #Innovation #RnD #Biotech #LifeScience #TheraVacBiotech #InSilico #AIinHealthcare #GlobalHealth #VaccineDevelopment #PeptideVaccine #Vaccine #PrecisionMedicine #Immunotherapy

Welcome to OmniTwin’s LinkedIn! We're here to transform industries through digital twins, advanced AI, and cutting-edge simulations. Let’s shape the future together—one twin at a time! 🌍✨ Dr. Isaad Sainkoudje Marie N. Mendez-Sainkoudje Sirrena Caelis Caroline Rodriguez Samuel Craft Raphael Wenninger TheraVac Biotech TeslaDuo Research SirrenaAI TradePharma Network TradePharmaDAO Omniversalis Impact Fund #AI #Decentralization #DigitalIdentity #DigitalTwins #CredentialingProcess #TechInnovation #Collaboration #Blockchain #Web3 #OmniTwin #OmniComm

🚀 In Progress: NeoVax Development for High-Impact Cancer Neoantigens 🚀 We're excited to share updates on the ongoing progress with #NeoVax, where we are harnessing top #neoantigen targets in our mission to advance personalized cancer immunotherapy. Below are the neoantigens currently being evaluated for their roles in driving aggressive cancers, with targeted mutation fragments, #HLA #binding data, and associated #cancer types: 1. KRAS (G12V)   - Associated Cancers: Pancreatic, colorectal, non-small cell lung cancer (NSCLC)   - HLA Type: HLA-A*11:01   - Binding Score: 35 nM (Strong Binding) 2. EGFR (L858R)   - Associated Cancers: NSCLC, glioblastoma   - HLA Type: HLA-A*02:01   - Binding Score: 80 nM (Intermediate Binding) 3. BRAF (V600E)   - Associated Cancers: Melanoma, colorectal, thyroid, NSCLC   - HLA Type: HLA-A*11:01   - Binding Score: 15 nM (Strong Binding) 4. HER2 (ERBB2)   - Associated Cancers: Breast, gastric, esophageal cancers   - HLA Type: HLA-A*02:01   - Binding Score: 120 nM (Intermediate Binding) 5. NY-ESO-1   - Associated Cancers: Melanoma, ovarian, lung, synovial sarcoma   - HLA Type: HLA-A*02:01   - Binding Score: 20 nM (Strong Binding) 6. MAGE-A3   - Associated Cancers: Melanoma, head and neck, bladder, lung cancers   - HLA Type: HLA-A*02:01   - Binding Score: 45 nM (Strong Binding) 7. WT1 (Wilms Tumor 1)   - Associated Cancers: Leukemia, ovarian, lung cancers   - HLA Type: HLA-A*02:01   - Binding Score: 30 nM (Strong Binding) 8. GPC3 (Glypican-3)   - Associated Cancers: Hepatocellular carcinoma (HCC), melanoma   - HLA Type: HLA-A*24:02   - Binding Score: 70 nM (Intermediate Binding) Each of these neoantigens shows potential for strong to intermediate binding with key HLA types, enhancing their immunogenicity and paving the way for highly personalized cancer treatments. #NeoVax is dedicated to refining these targets to bring transformative therapies to patients worldwide. Stay tuned as we move forward with innovative partnerships & groundbreaking results! Learn more and join us in shaping the future of precision oncology!🧬💡 Dr. Isaad Sainkoudje Marie N. Mendez-Sainkoudje Sirrena Caelis Caroline Rodriguez Samuel Craft Raphael Wenninger TradePharma Network TradePharmaDAO Omniversalis Impact Fund BayesLearn Systems SirrenaAI OmniversalisDAO #Innovation #RnD #Biotech #TheraVacBiotech #InSilico #AIinHealthcare #NeoAntigens #PeptideVaccine #PrecisionMedicine

The FDA recently approved alectinib (Alecensa) for people with non-small cell lung cancer who have ALK-positive tumors that can be removed with surgery. https://go.nih.gov/uGFEmVm

🚀🌟 Exciting News from TheraVac Biotech! 🌟🚀 We are thrilled to unveil an ultra-limited series of NFTs in collaboration with OmniversalisDAO 🛠️ to support the development of our pioneering TheraVac-AC-2 Peptide Vaccine for KRAS G12D-driven cancers. Powered by advanced in silico research 🧠, top-tier computational resources, and precision peptide engineering 🧬, these NFTs offer an exclusive opportunity to engage with the forefront of cancer therapy innovation 💪🧬 👉 https://lnkd.in/et3637bU As part of our commitment to advancing high-impact therapies and fostering groundbreaking partnerships within the life sciences and biotech communities 🌍, we’re releasing 100 premium NFTs. This limited series connects buyers with a unique stake in the early-stage advancement of TheraVac-AC-2, aligning them with our mission to revolutionize cancer treatment. Why Join Us? 1️⃣ Collaborative Partnerships: Join our journey in pushing the boundaries of #oncology 🩺 by contributing to the refinement and development of a next-generation cancer vaccine. 2️⃣ Elite Access: Each NFT holder gains access to exclusive project updates 📈 on TheraVac-AC-2, including milestone achievements, preclinical findings, and partnership opportunities. 3️⃣ Shared Vision for Impact: Be recognized as a key supporter of a transformative cancer therapy with the potential to redefine options for patients facing KRAS-driven cancers 🌟. If you’re an organization or individual passionate about groundbreaking cancer therapies and wish to be part of a bold vision in precision oncology, let’s connect! 💬 Interested in securing your place in this journey? Let’s work together to bring TheraVac-AC-2 to the forefront of cancer care 🏆 Dr. Isaad Sainkoudje Marie N. Mendez-Sainkoudje Caroline Rodriguez Sirrena Caelis Samuel Craft Raphael Wenninger TeslaDuo Research TradePharma Network TradePharmaDAO Omniversalis Impact Fund BayesLearn Systems SirrenaAI #Innovation #NFT #longevity #antiagingn #Biotech #InSilico #DeSci #TheraVacBiotech #shelterincomplex #Telomeres #DrugDiscovery #AI #Sirrena #BayesLearnSystem #cellularhealth #PeptideEngineering #PrecisionMedicine #IPprotection #NFT #Discoveria #TokenZu #TheraVac Feel free to reach out directly if you’re interested in this unique opportunity! 📩